APD125 for Insomnia
In December 2008, we announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicated that APD125 did not meet the trial's primary or secondary endpoints. Treatment with APD125 was well tolerated, and there were no reports of serious adverse events and no emerging safety findings as compared to placebo. We announced in December 2008 that we do not anticipate any further development of APD125.
Our product candidates have not been approved by the U.S. Food and Drug Administration or any international regulatory agency.
(This page was last updated: January 5, 2009. Additional information regarding Arena is available in its SEC filings.)
